Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 155,608
  • Shares Outstanding, K 21,200
  • Annual Sales, $ 20,060 K
  • Annual Income, $ -36,960 K
  • 36-Month Beta 3.28
  • Price/Sales 7.66
  • Price/Cash Flow N/A
  • Price/Book 1.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.97 +18.76%
on 05/21/18
7.49 -5.34%
on 06/20/18
+1.09 (+18.17%)
since 05/18/18
3-Month
5.50 +28.91%
on 05/14/18
21.26 -66.65%
on 03/23/18
-13.48 (-65.53%)
since 03/20/18
52-Week
5.50 +28.91%
on 05/14/18
23.97 -70.42%
on 03/09/18
-4.62 (-39.45%)
since 06/20/17

Most Recent Stories

More News
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that results of a Phase 1 study in healthy volunteers and supportive pre-clinical data for the Company's novel injectable hepcidin mimetic,...

PTGX : 7.09 (-3.41%)
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2018 JMP Securities Life Sciences...

PTGX : 7.09 (-3.41%)
Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that on May 31, 2018, it issued an inducement award to Samuel Saks, M.D., the Company's recently appointed Chief Development Officer, in accordance...

PTGX : 7.09 (-3.41%)
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Samuel Saks, M.D., as Chief Development Officer. In this newly-created role, Dr. Saks will provide strategic oversight of...

PTGX : 7.09 (-3.41%)
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was...

PTGX : 7.09 (-3.41%)
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down

Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.

PTGX : 7.09 (-3.41%)
LGND : 199.15 (+1.65%)
PBYI : 55.40 (-0.45%)
RHHBY : 27.0900 (+2.11%)
Protagonist Therapeutics Reports First Quarter 2018 Financial Results

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018.

PTGX : 7.09 (-3.41%)
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View

Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.

PTGX : 7.09 (-3.41%)
LGND : 199.15 (+1.65%)
INFI : 1.76 (-1.68%)
BMY : 54.25 (+1.14%)
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1

Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.

PTGX : 7.09 (-3.41%)
LGND : 199.15 (+1.65%)
RHHBY : 27.0900 (+2.11%)
EPZM : 15.90 (+6.35%)
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1

Merrimack (MACK) reports wider-than-expected loss in the first quarter.

PTGX : 7.09 (-3.41%)
LGND : 199.15 (+1.65%)
SHPG : 160.61 (+2.31%)
MACK : 9.54 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PTGX with:

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

2nd Resistance Point 7.70
1st Resistance Point 7.39
Last Price 7.09
1st Support Level 6.88
2nd Support Level 6.68

See More

52-Week High 23.97
Fibonacci 61.8% 16.91
Fibonacci 50% 14.73
Fibonacci 38.2% 12.56
Last Price 7.09
52-Week Low 5.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar